Clinical trials: Vitiligo
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks.
- Trial name
- NCT03715829
- Testing
- PF-06651600, PF06700841, narrow-band UVB phototherapy
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 366 people
- Sponsor
- Pfizer
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental…
- Trial name
- NCT04818346
- Testing
- INCB054707
- Where
- 31 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- Incyte Corporation
Vitiligo
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
- Trial name
- NCT04896385
- Testing
- Ruxolitinib cream, Vehicle Cream
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 60 people
- Sponsor
- Incyte Corporation
Vitiligo
A Trial of SHR0302Base in Patients With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.
- Trial name
- NCT06790862
- Testing
- SHR0302Base gel
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
- Trial name
- TONE (NCT05971381)
- Testing
- RECELL® Autologous Cell Harvesting Device
- Where
- 17 sites in United States
- Volunteers
- 109 people
- Sponsor
- Avita Medical
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Non-segmental Vitiligo
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
- Trial name
- NCT04487860
- Testing
- AS012
- Where
- 31 sites in United States, India
- Volunteers
- 327 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Vitiligo
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.
- Trial name
- NCT05210582
- Testing
- Afamelanotide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Clinuvel, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Vitiligo
A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo.
- Trial name
- NCT05053022
- Testing
- Skinpen Precision System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Crown Laboratories, Inc.
Non-segmental Vitiligo
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
- Trial name
- NCT07251595
- Testing
- SHR0302 Tablets, SHR0302 Base Gel
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo, Non-Segmental Vitiligo (NSV)
Study of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
- Trial name
- D2570-206 (NCT07625891)
- Testing
- D-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3
- Where
- China
- Volunteers
- 160 people
- Sponsor
- InventisBio Co., Ltd
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
The purpose of this study is to look at the efficacy of afamelanotide, when combined with narrow-band ultraviolet B (NB-UVB) light, in patients with nonsegmental vitiligo.
- Trial name
- CUV102 (NCT01430195)
- Testing
- Afamelanotide, Narrow-Band UVB Light Treatment
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Non-Segmental Vitiligo (NSV)
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.
- Trial name
- NCT07556471
- Testing
- Experimental LW402 Tablet
- Volunteers
- 180 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation